Evidence for cytotoxic T lymphocyte response against human lung cancer: Reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I

Surgery

Volumn 128, Issue 1, 2000, Pages 76-85

  Calhoun II, Royce F ^b   Naziruddin, Bashoo ^b   Enriquez Rincon, Fernando ^a,b   Duffy, Brian F ^b   Ritter, Jon M ^b   Sundaresan, Sudhir ^b   Patterson, G Alexander ^b   Cooper, Joel D ^b   Mohanakumar, Thalachallour ^b  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CANCER IMMUNOLOGY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0033921431     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1067/msy.2000.106639     Document Type: Article

References (27)

1. Slingluff CL, Hunt D, Engelhard VH. Direct analysis of tumor-associated peptide antigens. Curr Opin Immunol 1994;6:733-40.
2. + cytotoxic T lymphocytes. J Exp Med 1995;185:363-8.
3. Boon T, VanDer Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996;183:725-9.
4. + cytotoxic T lymphocytes. Cancer Res 1997;57:87-93.
5. Linehan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ. Tumor-specific and HLA-A2-restricted cytolysis by tumor associated lymphocytes in human metastatic breast cancer. J Immunol 1995;155:4486-91.
6. Pisani RJ. Bronchogenic carcinoma: immunologic aspects. Mayo Clin Proc 1993;68:386-92.
7. Seki N, Hoshino T, Kikuchi M, Hayashi A, Itoh K. HLA-A locus restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Cell Immunol 1997;175:101-10.
8. Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, et al. Identification of a tyrosinase epitope recognized by HLA-A244-estricted, tumor-infiltrating lymphocytes. J Immunol 1995;155:1343-48.
9. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 1994;264:716-9.
10. Romero P, Gervois N, Schneider J, Escobar P, Valmori D, Pannetier C, et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997;159:2366-74.
11. Pandolfino M, Viret C, Gervois N, Guillooux Y, Davodeau F, Diez E, et al. Specificity, T cell receptor diversity, and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Eur J Immunol 1992;22:1795-1802.
12. Ellis T, Mohanakumar T. Dissociation of autologous and allogeneic mixed lymphocyte reactivity by using a monoclonal antibody specific for human T helper cells. J Immunol 1983;131:2323-7.
13. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee H. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991;351:290-4.
14. Ikeda H, Lethe B, Lehman F, Van Baren N, Baurain J, DeSmet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
15. Maeurer MJ, Gollin SM, Martin D, Swaney W, Bryant J, Castelli C, et al. Tumor escape from immune recognition. J Clin Invest 1996;98:1633-41.
16. Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP 1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet 1996;2:210-3.
17. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487-94.
18. Poindexter N, Naziruddin B, McCourt DW, Mohanakumar T. Isolation of a kidney-specific peptide recognized by alloreactive HLA-A3 restricted human CTL. J Immunol 1995;154:3880-7.
19. Nguyen T, Naziruddin B, Dintzis S, Doherty GM, Mohanakumar T. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic lymphocytes. Int J Cancer 1999;81:607-15.
20. Melioli G, Ratto G, Guastella M, Meta M, Biassoni R, Semino C, et al. Isolation and in vitro expansion of lymphocytes infiltrating non-small cell lung carcinoma: functional and molecular characterization for their use in adoptive immunotherapy. Eur J Cancer 1994;30A:97-102.
21. Takahashi K, Sone S, Kimura S, Ogura T, Monden Y. Phenotypes and lymphokine activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Chest 1993;103:1732-38.
22. Slingluff CL, Cox AL, Stover JJM, Moore MM, Hunt D, Engelhard VH. Cytotoxic T lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68. Cancer Res 1994;54:2731-7.
23. Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopath 1986;38:367-80.
24. Yoshino I, Yano T, Murata M, Ishida T, Sugimachi K, Kimura G, et al. Tumor-reactive T cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res 1992;52:775-81.
25. Niehans GA, Brunner T, Frizelle SP, Liston JC, Salerno CT, Knapp DJ, et al. Human lung carcinomas express Fas ligand. Cancer Res 1997;6:1007-12.
26. Lawrence DA, Weigle WO, Spiegelberg HL. Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils. J Clin Invest 1975;55:368-76.
27. Denissenko MF, Pao A, Tang M, Pheifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hot spots. Science 1996;274:430-2.